Predictive Parameters of Febrile Neutropenia and Clinical Significance of G-CSF Receptor Signaling Pathway in the Development of Neutropenia during R-CHOP Chemotherapy with Prophylactic Pegfilgrastim in Patients with Diffuse Large B-Cell Lymphoma
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose: Pegfilgrastim is widely used to prevent chemotherapy-induced neutropenia (CIN) and febrile neutropenia (FN) in patients with diffuse large B-cell lymphoma (DLBCL). We investigated the predictive factors affecting CIN and FN incidence in patients with DLBCL receiving rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy with pegfilgrastim and conducted experiments to find reason for the occurrence of CIN even when pegfilgrastim was used. Materials and methods: We reviewed the CIN and FN events of 200 patients with DLBCL. Based on these data, we investigate the association with predictive factor and the levels of granulocyte-colony stimulating factor (G-CSF) receptor signaling pathway markers (pSTAT3, pAKT, pERK1/2, pBAD, and CXCR4) in bone marrow (BM) samples isolated from patients with DLBCL. Results: FN was significantly associated with stage III/IV (hazard ratio [HR], 12.74) and low serum albumin levels (HR, 3.87). Additionally, patients with FN had lower progression-free survival (PFS; 2-year PFS, 51.1 % vs. 74.0%) and overall survival (OS; 2-year OS, 58.2% vs. 85.0%) compared to those without FN. The occurrence of CIN was associated with overexpression of G-CSF receptor signaling pathway markers, and expression levels of these markers were upregulated in BM cells co-cultured with DLBCL cells. The rate of neutrophil apoptosis was also higher in neutrophils co-cultured with DLBCL cells and was further promoted by treatment with doxorubicin. Conclusion: Our findings suggest that high DLBCL burden may alter the BM environment and G-CSF receptor signaling pathway, even in chemotherapy-naïve state, which may increase CIN frequency during R-CHOP chemotherapy.
Abstract
Purpose: Pegfilgrastim is widely used to prevent chemotherapy-induced neutropenia (CIN) and febrile neutropenia (FN) in patients with diffuse large B-cell lymphoma (DLBCL). We investigated the predictive factors affecting CIN and FN incidence in patients with DLBCL receiving rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy with pegfilgrastim and conducted experiments to find reason for the occurrence of CIN even when pegfilgrastim was used. Materials and methods: We reviewed the CIN and FN events of 200 patients with DLBCL. Based on these data, we investigate the association with predictive factor and the levels of granulocyte-colony stimulating factor (G-CSF) receptor signaling pathway markers (pSTAT3, pAKT, pERK1/2, pBAD, and CXCR4) in bone marrow (BM) samples isolated from patients with DLBCL. Results: FN was significantly associated with stage III/IV (hazard ratio [HR], 12.74) and low serum albumin levels (HR, 3.87). Additionally, patients with FN had lower progression-free survival (PFS; 2-year PFS, 51.1 % vs. 74.0%) and overall survival (OS; 2-year OS, 58.2% vs. 85.0%) compared to those without FN. The occurrence of CIN was associated with overexpression of G-CSF receptor signaling pathway markers, and expression levels of these markers were upregulated in BM cells co-cultured with DLBCL cells. The rate of neutrophil apoptosis was also higher in neutrophils co-cultured with DLBCL cells and was further promoted by treatment with doxorubicin. Conclusion: Our findings suggest that high DLBCL burden may alter the BM environment and G-CSF receptor signaling pathway, even in chemotherapy-naïve state, which may increase CIN frequency during R-CHOP chemotherapy.
참고문헌 (30)
- Morton LM, "Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium(InterLymph)", Blood, 110, pp.695~708 (2007)
- Lee L, "Impact of rituximab on treatment outcomes of patients with diffuse large b-cell lymphoma : a population-based analysis", Br J Haematol, 158, pp.481~488 (2012)
- Lindenmeyer LP, "Follow-up of patients receiving rituximab for diffuse large B cell lymphoma : an overview of systematic reviews", Ann Hematol, 92, pp.1451~1459 (2013)
- Crawford J, "Chemotherapy-induced neutropenia : risks, consequences, and new directions for its management", Cancer, 100, pp.228~237 (2004)
- Kuderer NM, "Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients", Cancer, 106, pp.2258~2266 (2006)
- Bosly A, "Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B-cell lymphoma patients treated with CHOP", Ann Hematol, 87, pp.277~283 (2008)
- Lyman GH, "Impact of chemotherapy dose intensity on cancer patient outcomes", J Natl Compr Canc Netw, 7, pp.99~108 (2009)
- Aapro MS, "2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours", Eur J Cancer, 47, pp.8~32 (2011)
- "Hematopoietic growth factors (version 4.2021)" (2021)[URL]
- Maher DW, "Filgrastim in patients with chemotherapy-induced febrile neutropenia : a double-blind, placebo-controlled trial", Ann Intern Med, 121, pp.492~501 (1994)
- Cooper KL, "Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy : systematic review and meta-analysis", BMC Cancer, 11, pp.404~ (2011)
- Tidow N, "Advances in understanding postreceptor signaling in response to granulocyte colony-stimulating factor", Curr Opin Hematol, 4, pp.171~175 (1997)
- Demetri GD, "Granulocyte colony-stimulating factor and its receptor", Blood, 78, pp.2791~2808 (1991)
- Yang BB, "Pharmacokinetics and pharmacodynamics of pegfilgrastim", Clin Pharmacokinet, 50, pp.295~306 (2011)
- Green MD, "A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy", Ann Oncol, 14, pp.29~35 (2003)
- Holmes FA, "Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in pati-ents with high-risk stage II or stage III", IV breast cancer, 2002, pp.20, 727~731
- Brusamolino E, "Dose-dense R-CHOP-14 supported by pegfilgrastim in patients with diffuse large B-cell lymphoma : a phase II study of feasibility and toxicity", Haematologica, 91, pp.496~502 (2006)
- Yokoyama M, "Incidence and risk factors of febrile neutropenia in patients with non-Hodgkin B-cell lymphoma receiving R-CHOP in a single center in Japan", Support Care Cancer, 25, pp.3313~3320 (2017)
- Lyman GH, "Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma", Cancer, 98, pp.2402~2409 (2003)
- Lyman GH, "Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin’s lymphoma receiving CHOP chemotherapy", Leuk Lymphoma, 44, pp.2069~2076 (2003)
- Morrison VA, "Patterns of growth factor usage and febrile neutropenia among older patients with diffuse large B-cell non-Hodgkin lymphoma treated with CHOP or R-CHOP : the Intergroup experience(CALGB 9793; ECOG-SWOG 4494)", Leuk Lymphoma, 58, pp.1814~1822 (2017)
- Ray-Coquard I, "Baseline and early lymphopenia predict for the risk of febrile neutropenia after chemotherapy", Br J Cancer, 88, pp.181~186 (2003)
- Lyman GH, "Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy : a systematic review", Crit Rev Oncol Hematol, 90, pp.190~199 (2014)
- 이동건, "Evidence-Based Guidelines for Empirical Therapy of Neutropenic Fever in Korea", The Korean Journal of Internal Medicine, 26(2), pp.220~252 (2011), 대한내과학회
- 최용원, "Patterns of Neutropenia and Risk Factors for Febrile Neutropenia of Diffuse Large B-Cell Lymphoma Patients Treated with Rituximab-CHOP", Journal of Korean Medical Science, 29(11), pp.1493~1500 (2014), 대한의학회
- Fukunaga R, "Growth and differentiation signals mediated by different regions in the cytoplasmic domain of granulocyte colony-stimulating factor receptor", Cell, 74, pp.1079~1087 (1993)
- Santini V, "The carboxy-terminal region of the granulocyte colony-stimulating factor receptor transduces a phagocytic signal", Blood, 101, pp.4615~4622 (2003)
- Palande K, "Scratching the surface : signaling and routing dynamics of the CSF3 receptor", Front Biosci(Landmark Ed), 18, pp.91~105 (2013)
- Ok CY, "Clinical implications of phosphorylated STAT3 expression in de novo diffuse large B-cell lymphoma", Clin Cancer Res, 20, pp.5113~5123 (2014)
- Hong JY, "The impact of activated p-AKT expression on clinical outcomes in diffuse large B-cell lymphoma : a clinicopathological study of 262 cases", Ann Oncol, 25, pp.182~188 (2014)